Moderna CEO Stéphane Bancel joins ‘Mornings with Maria’ to discuss the company’s landmark cancer vaccine partnership with Merck. Bancel details the promising Phase 3 melanoma trial results and outlines Moderna’s latest financial growth outlook.
Moderna’s landmark cancer vaccine breakthrough is detailed by CEO Stéphane Bancel on ‘Mornings with Maria.’ Speaking with Cheryl Casone, Bancel highlights promising trial data showing the mRNA vaccine reduced melanoma recurrence risk. He also breaks down the company’s second-quarter earnings report, noting $145 million in revenue and plans for future pipeline expansion.
Read the full article here